Word: suitors
(lookup in dictionary)
(lookup stats)
Dates: all
Sort By: most recent first
(reverse)
...Boston Globe reported Friday that though Boston College (BC) is a leading contender, “some speculation” indicates that Harvard could be “another suitor...
...isolated in the mountains herding yaks with an uncle who never speaks. She jealously punishes her sister by feeding her a sausage of human feces to protest her sister's larger portions of meat. By the final pages of the book, Namu has beaten two people bloody, devastated a suitor, demolished a kitchen with an axe and fled her village with her mother flinging stones at her back. Through it all, she remains likable: you have to root for a girl trying so hard to leave her village on her own terms, something her mother tried to do but failed...
...several cable channels and the Universal movie studio. Late last year, Texas oilman Marvin Davis offered $20 billion for the U.S. assets, and Vivendi acted insulted; a Vivendi official at the time suggested that Davis "take a hike." That bit of pride is proving costly. Last week, a promising suitor, MGM, pulled out of the auction, saying the price Vivendi now seeks - $14 billion - is too high. MGM reckoned the package was worth no more than $11.5 billion. Two days later, Viacom hinted its interest had waned. That leaves only three bidders, some of which won't pay cash...
...operations side, not as a scientist. His big coups at Biogen were beefing up manufacturing capacity and creating the industry's most extensive sales force. So he's well suited to his task. But even if his deal goes through (Genentech is seen as a competing suitor for IDEC), and even if he manages to instill new management intensity in the industry, biotech will remain a dicey game. Only one drug in 5,000 screened makes it to market. "We'll take the risk that a company fails to execute its plan once it has a drug approval," says Stuart...
...even if his deal goes through (Genentech is seen as a competing suitor for IDEC) and even if he manages to instill a new level of management intensity in the industry, biotech will remain a dicey game. Only one drug in 5,000 screened makes it to market, and even seasoned health-care investors are reluctant to handicap the process. "We'll take the risk that a company fails to execute its plan once it has a drug approval," says Stuart Weisbrod, chief investment officer of Merlin Biomed, a health-care hedge fund. "What we don't want...